Trial Profile
Survival of patients with recurrent glioblastoma multiforme treated with local carmustine wafer (Gliadel) in relation to the methylation of methylguanin-DNA-methyltransferase (MGMT) promotor
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Carmustine polifeprosan 20 wafer (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 03 Jan 2022 Status changed from active, no longer recruiting to completed.
- 01 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 01 Apr 2020 Planned End Date changed from 30 Sep 2018 to 31 Dec 2021.